Onabotulinumtoxin A Treatment of Drooling in Children with Cerebral Palsy: A Prospective, Longitudinal Open-Label Study
Autor: | Pia Svendsen, Allan Bardow, Joan Lykkeaa, Merete Bakke, Søren Anker Pedersen, Pablo Gustavo Vinicoff, Eigild Møller |
---|---|
Rok vydání: | 2015 |
Předmět: |
Male
medicine.medical_specialty Adolescent Health Toxicology and Mutagenesis Submandibular Gland lcsh:Medicine drooling Toxicology Drooling Article Cerebral palsy Open label study stomatognathic system children medicine Humans Parotid Gland Longitudinal Studies Prospective Studies botulinum toxin Botulinum Toxins Type A Onabotulinumtoxin a Prospective cohort study Child salivary flow cerebral paresis Dose-Response Relationship Drug business.industry Cerebral Palsy lcsh:R Sialorrhea medicine.disease Submandibular gland Botulinum toxin Surgery Parotid gland stomatognathic diseases medicine.anatomical_structure Treatment Outcome Anesthesia Child Preschool Female medicine.symptom business medicine.drug |
Zdroj: | Toxins Volume 7 Issue 7 Pages 2481-2493 Toxins, Vol 7, Iss 7, Pp 2481-2493 (2015) |
ISSN: | 2072-6651 |
Popis: | The aim of this prospective open-label study was to treat disabling drooling in children with cerebral palsy (CP) with onabotulinumtoxin A (A/Ona, Botox®) into submandibular and parotid glands and find the lowest effective dosage and least invasive method. A/Ona was injected in 14 children, Mean age 9 years, SD 3 years, under ultrasonic guidance in six successive Series, with at least six months between injections. Doses and gland involvement increased from Series A to F (units (U) per submandibular/parotid gland: A, 10/0 B, 15/0 C, 20/0 D, 20/20 E, 30/20 and F, 30/30). The effect was assessed 2, 4, 8, 12, and 20 weeks after A/Ona (drooling problems (VAS), impact (0–7), treatment effect (0–5), unstimulated whole saliva (UWS) flow and composition)) and analyzed by two-way ANOVA. The effect was unchanged–moderate in A to moderate–marked in F. Changes in all parameters were significant in E and F, but with swallowing problems ≤5 weeks in 3 of 28 treatments. F had largest VAS and UWS reduction (64% and 49%). We recommend: Start with dose D A/Ona (both submandibular and parotid glands and a total of 80 U) and increase to E and eventually F (total 120 U) without sufficient response. |
Databáze: | OpenAIRE |
Externí odkaz: |